Skip to content

Quantum Dots for Medicine Current Applications, Challenges, and Future Directions - A Comprehensive Review

FieldValue
JournalZenodo (CERN European Organization for Nuclear Research)
Published2026-04-23
AuthorsAbhinav Dupare*, Nitin Padole, Pankaj Dhapke , Nilakshi Dhoble, Jagdish Baheti
DOI10.5281/zenodo.19703487

A review of 70 cited works finds that 1 to 10 nm semiconductor quantum dots offer photostable, size-tunable fluorescence for multiplexed diagnostics and long-term bioimaging. It also finds that toxicity, long-term retention, weak reproducibility, manufacturing scale, and absent regulatory standards still block clinical translation.

The review synthesizes cited work on material types, diagnostic and therapeutic uses, progress from 2021 to 2025, and barriers to clinical translation. Its reference list runs from 1 to 70 and includes earlier foundational studies.

The paper is a narrative review, not a new experiment. It reports no database search, inclusion criteria, effect-size calculation, or pooled clinical comparison. Its tables map claims and material tradeoffs rather than rank clinical performance.

Quantum confinement links particle size to optical behavior. The review covers semiconductor, carbon, graphene, black phosphorus, perovskite, and diamond quantum materials.

MaterialSizeMain propertiesStated limitations
Semiconductor QDs, including CdSe, CdTe, and InP1 to 10 nmTunable fluorescence, high quantum yield, narrow emissionHeavy-metal toxicity, long-term retention
Carbon QDs<10 nmMetal-free fluorescence, high water solubilityLower brightness
Graphene QDs<20 nmNear-infrared absorption, photothermal conversionStability, batch variability
Black phosphorus QDs2 to 10 nmNear-infrared absorption, high photothermal efficiencyOxidation, chemical instability
Perovskite QDs5 to 15 nmUltra-narrow emission, very high photoluminescence efficiencyLead toxicity, poor stability
NV-center nanodiamonds5 to <100 nmSpin coherence, magnetic sensitivityCost, complex instrumentation

Carbon QDs overlap with the smallest semiconductor QDs in size, but the review reports lower brightness than semiconductor QDs. Perovskite QDs offer the narrowest listed emission, while lead content and poor stability constrain in vivo use.

GQDs and black phosphorus QDs support near-infrared photothermal treatment, but black phosphorus QDs require stabilization in oxygen-rich media. Smaller quantum-dot radii can shift excitation peaks toward blue wavelengths. Electric tuning of excitons in two-dimensional semiconductors and control of refractive-index changes remain research directions.

Quantum-dot biosensors combine a biological recognition element with a signal transducer. The review lists immunoassays and microarrays for cancer and cardiac biomarkers, nucleic-acid tests for DNA, RNA, and miRNA, and liquid biopsy for circulating tumor cells and exosomes. It reports low detection limits and multiplexed detection, but gives no numerical limit that can be compared across platforms.

For cellular imaging, quantum dots and carbon quantum dots support long-term tracking and multicolor imaging. Near-infrared quantum dots and graphene quantum dots are associated with deep-tissue penetration and high contrast in in vivo tumor imaging. These are application claims drawn from cited studies, not a common quantitative benchmark.

Surface functionalization determines water dispersibility, biological compatibility, and biomarker targeting through antibodies, peptides, aptamers, or small molecules. Differences in functionalization, synthesis, and biological settings complicate comparisons of sensitivity and specificity. The review therefore identifies standard evaluation procedures as a requirement.

Multiplexed platforms can detect proteins, nucleic acids, and metabolites together for molecular typing and personalized profiles. The authors present this as a route toward early diagnosis and relapse assessment, without reporting patient outcomes or clinical performance.

The review groups therapy by trigger and function. Quantum dots, carbon quantum dots, and graphene quantum dots can carry drugs under pH, enzyme, or ligand control. Across the nanocarrier strategies discussed, antibodies, peptides, folic acid, and aptamers support active uptake through receptor-mediated endocytosis. Carbon quantum dots are also listed for gene delivery with real-time tracking. No loading efficiency, transfection efficiency, or dose appears in the review.

Photodynamic therapy uses wavelength-selected light to activate a photosensitizer and generate reactive oxygen species. The review attributes localized cell destruction to that process and lists cancer and infections as targets. Photothermal therapy uses near-infrared light to heat tissue locally. Graphene quantum dots and black phosphorus quantum dots are the listed photothermal materials.

Combined photothermal and photodynamic treatment uses heat-assisted oxygen perfusion with reactive-oxygen production. The authors describe this as a way to improve tumor killing under hypoxia. They also report that adding chemotherapy or immunotherapy can improve drug release, cellular uptake, or immune response. These are reported mechanistic and preclinical benefits, not clinical efficacy values.

Theranostic systems combine imaging with therapy. The review discusses multifunctional quantum dots and metal-organic-framework-derived systems that respond to pH, redox potential, or enzyme activity. It also lists carbon quantum dots for light-induced reactive oxygen species against multidrug-resistant infections, although the accompanying discussion gives more attention to natural products than quantum-dot studies.

NV centers arise from a substitutional nitrogen atom next to a lattice vacancy in diamond. Spin-dependent fluorescence provides optical initialization and readout. The review says these defects can detect very weak thermal, electric, and magnetic signals under physiological conditions while imaging neuronal activity and intracellular communication.

The cited prior work includes optical magnetic detection of single-neuron action potentials using diamond quantum defects. This is evidence from an earlier study, not a new result generated by the review. Compared with MRI, the authors describe NV sensing as avoiding the need for very large magnetic fields and offering higher spatial resolution.

Long spin coherence and photostability support continuous monitoring in dynamic biological media. The review identifies cost and complex instrumentation as practical limitations. It provides no defect density, crystal orientation, coherence time, detection threshold, or spatial resolution, so it cannot define an NV sensor material specification.

Translation barriers and proposed directions

Section titled “Translation barriers and proposed directions”

Research progress from 2021 to 2025 included carbon, graphene, and silicon quantum dots intended to reduce the toxicity problems of metal-based systems. Surface engineering was used to add targeting ligands and therapeutic cargo. The review treats biodegradable and metal-free materials as future priorities rather than resolved clinical solutions.

The stated biological barriers are ion leakage from lead- or cadmium-containing particles, long-term biodistribution and accumulation, and protein-corona formation. A protein corona can change targeting, optical behavior, and surface properties in vivo. Batch-to-batch variation affects repeatability, especially for carbon and graphene quantum dots.

Manufacturing scale remains a barrier for large nanoparticle synthesis. A theranostic product faces both diagnostic and therapeutic safety requirements. The authors also report that uniform evaluation standards are absent because studies use different synthesis, functionalization, and biological settings.

Artificial intelligence is proposed for predicting material properties, toxicity, and biological interactions. It may also support fluorescence interpretation, synthesis optimization, and integration with microfluidics and digital health. The review presents these as proposed directions and supplies no validated clinical performance result for the combined workflow.

Material selection should follow the application. Multiplexed optical assays should compare semiconductor quantum dots for photostable emission with carbon quantum dots for metal-free formulation. Photothermal work should test graphene quantum dots and black phosphorus quantum dots with explicit stability controls. The review places perovskite quantum dots mainly in in vitro imaging and sensing because of lead toxicity and poor stability. NV sensing requires defect and optical specifications before any diamond is selected.

The review cannot supply procurement thresholds for sensitivity, quantum yield, photothermal conversion, toxicity, clearance, or batch variance. Its descriptions of ultra-high sensitivity remain qualitative. A development program should establish those values on one assay under matched biological conditions before selecting a material or moving toward clinical studies.

The paper’s diamond requirement is an NV-center quantum sensor for neuronal and cardiac imaging, with nanodiamonds listed at 5 to <100 nm. The paper gives no defect density, crystal orientation, coherence time, or detection threshold; the engineering support page can assess what a custom sensor requires before a material is selected. 6CCVD’s diamond materials catalog lists MPCVD-grown single-crystal and polycrystalline plates and wafers up to 125 mm, with thickness from 0.1 to 500 micrometers.

View Original Abstract

Quantum nanomaterials are revolutionizing the field of precision medicine by allowing diagnostic and therapeutic procedures at the molecular and subcellular level. Of these, semiconductor quantum dots, carbon quantum dots, graphene-based quantum nanostructures, and quantum sensing platforms are characterized by their unique optical, electronic, and magnetic properties, which are a result of quantum confinement effects and other quantum phenomena. These properties, including size-dependent fluorescence, sharp emission spectra, high photostability, and ultra-high sensitivity, have made quantum nanomaterials valuable tools for bioimaging, biosensing, targeted drug delivery, and theranostic applications. In the diagnostic area, quantum dots provide ultra-high sensitivity and multiplex analysis for the detection of disease biomarkers, which is crucial for early diagnosis and molecular typing, a requirement for personalized medicine. In the field of therapeutics, quantum nanomaterials are used as carriers for drugs and genes, photosensitizers for photodynamic and photothermal therapies, and as multifunctional platforms that integrate imaging and therapeutic modalities into a single device. On the other hand, quantum sensing technologies such as nitrogen-vacancy centers in diamond and atomic magnetometers are being developed for ultra-sensitive and label-free medical imaging and functional diagnostics. Although there has been great progress in the preclinical stage, translation to the clinical stage has been impeded by several issues regarding toxicity, long-term biocompatibility, scalability of manufacturing, and regulatory issues. This review article aims to give a comprehensive and critical assessment of the types of quantum nanomaterials, their applications in diagnosis and therapy, recent progress in research, and challenges in translation. Finally, future directions are also presented, focusing on biodegradable and metal-free quantum materials, multimodal theranostic platforms, and the integration of quantum